Do steroids effectively treat primary inflammatory demyelinating neuropathies such as chronic inflammatory demyelinating polyneuropathy (CIDP) but not secondary demyelinating neuropathies?

Steroids Work for Primary Demyelinating Neuropathies (CIDP) But NOT for Secondary Demyelinating Neuropathies

Corticosteroids are effective for primary inflammatory demyelinating neuropathies like CIDP, but they do not work for secondary demyelinating neuropathies such as multifocal motor neuropathy (MMN) or paraproteinemic demyelinating neuropathy (PDN). 1

Primary Demyelinating Neuropathy: CIDP

Evidence for Steroid Efficacy

For CIDP specifically, steroids are a proven first-line treatment:

• Randomized controlled trials demonstrate that corticosteroids reduce impairment in CIDP 2, though the evidence base consists of relatively small studies (one key RCT had only 35 participants)
• Multiple corticosteroid regimens show equivalent efficacy 3:
  • Daily oral prednisolone
  • Pulsed oral dexamethasone
  • Pulsed intravenous methylprednisolone

Treatment Response Rates

• 60% of CIDP patients respond to corticosteroids 3
• Of those who respond, 61% achieve sustained remission during median 55-month follow-up 3
• The 5-year remission probability for responders is 55% 3

Clinical Application

Corticosteroids remain one of three equally effective first-line options for CIDP, alongside intravenous immunoglobulin (IVIg) and plasma exchange 1, 4. The choice depends on patient factors, availability, and side effect profile considerations.

Secondary Demyelinating Neuropathies: Where Steroids FAIL

Multifocal Motor Neuropathy (MMN)

Steroids are NOT beneficial in MMN and should be avoided 1. This is a critical distinction:

• MMN responds ONLY to IVIg 5, 4
• Using steroids in MMN represents a common diagnostic pitfall
• If a patient diagnosed with "CIDP" fails to respond to steroids, reconsider whether they actually have MMN

Paraproteinemic Demyelinating Neuropathy (PDN)

The efficacy of steroids in PDN is uncertain and generally poor 1:

• Therapeutic strategies mirror those for CIDP, but clinical response is typically worse 4
• IVIg shows benefit specifically for IgM-associated PDN 1
• Plasma exchange may help IgG or IgA PDN, but steroid efficacy remains unproven 1

Key Clinical Pitfalls to Avoid

1. Misdiagnosis is common in CIDP 6 - if there's no treatment response to steroids, reconsider the diagnosis entirely
2. Don't use steroids for MMN - this can delay appropriate IVIg therapy
3. Monitor for steroid dependency - patients with dramatically slow motor conduction velocities at baseline are more likely to become steroid-dependent 7
4. Long-term steroid risks are significant 2 - the risk-benefit profile for chronic use has not been adequately studied

Algorithmic Approach to Treatment Selection

For suspected primary inflammatory demyelinating neuropathy:

1. Confirm diagnosis meets EFNS/PNS criteria for CIDP (not MMN or PDN)
2. If typical CIDP → Choose from three equally effective options: corticosteroids, IVIg, or plasma exchange 1
3. If motor-predominant or pure motor → Consider MMN instead → Use IVIg only, NOT steroids
4. If paraproteinemia present → IVIg preferred over steroids (especially for IgM type)

The fundamental distinction is autoimmune pathophysiology: Primary inflammatory neuropathies like CIDP respond to immune suppression with steroids, while secondary demyelinating processes (MMN, PDN) have different pathogenic mechanisms that do not respond to corticosteroid therapy 1, 5.